Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.

Ramez Nassef Eskander, Michael Sill, Lindsey Beffa et al. Jun 01, 2026 pp. 5502-5502 10.1200/jco.2026.44.16_suppl.5502

5502 Background: NRG-GY018, the only phase 3 trial examining dMMR and pMMR EC populations independently, identified a 70%...

Phase 1 study of META 10-19, an IL-10-expressing, anti-CD19 CAR T cell product in patients with high-risk DLBCL.

Qianwen Xu, Chongling Liu, Min Gao et al. Jun 01, 2026 pp. 2552-2552 10.1200/jco.2026.44.16_suppl.2552

2552 Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of B cell lymphoma. Howev...

A phase II trial of olaparib in combination with pembrolizumab in metastatic uveal melanoma.

Nikhil I. Khushalani, Michael J. Schell, Jiannong Li et al. Jun 01, 2026 pp. 9553-9553 10.1200/jco.2026.44.16_suppl.9553

9553 Background: Metastatic uveal melanoma (mUM) has a poor prognosis with modest response to immune checkpoint blockade (...

Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.

Maher Albitar, Wojciech Swat, Ahmad Charifa et al. Jun 01, 2026 pp. 1035-1035 10.1200/jco.2026.44.16_suppl.1035

1035 Background: Breast cancer (BrC) central nervous system (CNS) metastases are believed to be biologically and therapeut...

RET fusion–positive lung adenocarcinoma: Partner-specific clinicopathological characteristics, co-mutation profiles, and implications for targeted and immunotherapy.

Zihan Sun, Jianming Ying, Weihua Li et al. Jun 01, 2026 pp. 8615-8615 10.1200/jco.2026.44.16_suppl.8615

8615 Background: RET fusions represent actionable oncogeni...

Five-year outcomes of osimertinib-based treatment in a phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin plus pemetrexed as a first-line treatment for advanced non-squamous non–small-cell lung cancer harboring <i>EGFR</i> mutation (JCOG1404/WJOG8214L).

Shintaro Kanda, Tomonori Mizutani, Shogo Nomura et al. Jun 01, 2026 pp. 8649-8649 10.1200/jco.2026.44.16_suppl.8649

8649 Background: JCOG1404/WJOG8214L was an open label, multicenter, randomized phase III study comparing EGFR-TKI monother...

In-hospital complications and outcomes of autologous stem cell transplantation in diffuse large B-cell lymphoma with and without chronic kidney disease.

Jeet Patel, Marisa Vander Feen, Jane Broxterman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19109

e19109 Background: Chronic kidney disease (CKD) may increase transplant-related toxicity during autologous stem cell trans...

Thyroid cancer risk in systemic lupus erythematosus: A population-based retrospective cohort study.

Faiqa Amin, Madho Mal, Nayanika Chowdary Tummala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18043

e18043 Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked by immune dysregulation and l...

Trends, outcomes, and disparities in lung cancer–related hospitalizations in the United States: 2012–2022.

Katherine E. Guardado, Paul Wasuwanich, Jorge Arturo Rios-Perez Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20112

e20112 Background: Lung Cancer remains a leading cause of morbidity and mortality in the United States and accounts for si...

Bridging gaps in relapsed/refractory follicular lymphoma care: Perceived barriers to treatment and clinical trial access.

Carolyn Trachtenbroit, Caroline Offit, Nicole A. Colwell et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13547

e13547 Background: Despite expanding therapeutic options and clinical guidelines for relapsed/refractory follicular lympho...

Bladder preservation in patients with urothelial muscle-invasive bladder cancer who refused radical cystectomy after clinical complete response to trans-urethral resection of bladder tumors and neoadjuvant systemic chemotherapy. A retrospective single-center experience.

Savino Mauro Di Stasi, Redon Syrixhi, Elena Di Stasi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16585

e16585 Background: Neoadjuvant systemic chemotherapy (NASCT) followed by radical cystectomy (RC) is widely used among the...

Evaluation of circulating tumor DNA (ctDNA) following liver resection in a high-risk population with colorectal liver metastases.

John Neil Primrose, Robert Peter Jones, Naureen Starling et al. Jun 01, 2026 pp. 3556-3556 10.1200/jco.2026.44.16_suppl.3556

3556 Background: Liver resection is routinely performed for oligometastatic colorectal cancer (CRC). ctDNA analysis is bec...

Risk factors in association with adrenal insufficiency in hospitalized solid tumor patients on immunotherapy.

Sharon Hechter, Mahmoud Allahham, Venkata Sri Ramani Peesapati et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24183

e24183 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy and significantly improved clinical...

Burden of early-onset cancers in Hungary: Nationwide trends in incidence and mortality.

Otilia Menyhart, Zsolt Nagy, Balint Laszlo Balint et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22616

e22616 Background: Cancers diagnosed before 50 years of age (“early-onset” cancers) are increasingly recognized as a disti...

Real-world outcomes of mogamulizumab retreatment in cutaneous T-cell lymphoma: A single-center retrospective study.

Shahzeem Bhayani, Amy Liao, Marcus Paul Watkins et al. Jun 01, 2026 pp. 7096-7096 10.1200/jco.2026.44.16_suppl.7096

7096 Background: Mogamulizumab, monoclonal antibody against CCR4, is approved for relapsed/refractory cutaneous T cell lym...

Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.

Samantha Martin, Emily Blair, Sarah Sexton et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps10058

TPS10058 Background: Neuroblastoma is a malignant childhood tumor of the sympathetic nervous system. Cure rates are unsati...

Shifting patterns in PMBCL and DLBCL care: The role of community oncology centers in the U.S.

Maxine Diehl, Ekaterina Ponomareva, Sri Saikumar Sankaranarayanan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19071

e19071 Background: Historically, clinical trials and adoption of novel therapies for oncology have been concentrated withi...

Facility-level differences and outcomes in elderly primary CNS lymphoma in the NCDB.

Ysaith Orellana Ascencio, Guilherme Fleury Perini, Rosa Oliday et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13762

e13762 Background: PCNSL is a rare, aggressive subtype of non-Hodgkin lymphoma with increasing incidence in the U.S (ACSPM...

Assessing current sleep–cognition evidence and translation into oncology practice.

Yosra Raziani, Ahmad Nazari Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24129

e24129 Background: Despite strong evidence linking sleep disturbance with cognitive outcomes in cancer survivors, oncology...

Prevalence of oral and genital HPV-45 and non–vaccine-targeted HPV-35 among U.S. adults.

Morgan C. Byrd, Alexandra Hunter, Vincent M. D’Anniballe et al. Jun 01, 2026 pp. 10597-10597 10.1200/jco.2026.44.16_suppl.10597

10597 Background: High-risk human papillomavirus (HPV) types 35 and 45 are oncogenic non-16/18 subtypes that contribute me...

Global sex-based disparities in pancreatic cancer clinical trial enrollment: A systematic review and meta-analysis.

Amir H. Sohail, Abdul Rafeh Awan, Muhammad Ahmad Nadeem et al. Jun 01, 2026 pp. 1654-1654 10.1200/jco.2026.44.16_suppl.1654

1654 Background: Sex-based disparities in oncology trial enrollment are well recognized, yet their magnitude and consisten...

Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.

Vinod Ravi, Vishal Ghori, Aimar Zhang et al. Jun 01, 2026 pp. 11571-11571 10.1200/jco.2026.44.16_suppl.11571

11571 Background: TGCT is a rare, locally aggressive, soft-tissue tumor associated with significant morbidity. Pimicotinib...

Real-world pregnancy outcomes following temporary interruption of adjuvant endocrine therapy in early-stage hormone receptor–positive breast cancer.

Akshara Singareeka Raghavendra, Wenjie Zhu, Limin Hsu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12702

e12702 Background: The POSITIVE trial established the feasibility of temporary interruption of adjuvant endocrine therapy...

The impact of potentially inappropriate medications on performance status, functional status, and overall survival in older adults with prostate cancer.

Sam Joseph King, Ariana N. Neely, Akshay Ratnani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17018

e17018 Background: The 2023 American Geriatric Society's Beers Criteria lists around 100 medications with potential side e...

Integrated genomic and transcriptomic profiling of a breast cancer cohort in the UAE compared with TCGA.

Zhong Wee Poh, Keerthana Kathavarayan, Jia Hui Liew et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13015

e13015 Background: Breast cancer (BC) in the United Arab Emirates (UAE) remains under-characterized relative to large refe...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page